Humacyte's shares rose 9.9% post-earnings, reflecting positive market reception to progress in commercial expansion of Symvess, international regulatory advancements, and significant cost reductions from restructuring initiatives.

• First quarter Symvess sales grew to $0.5 million, up from $0.1 million a year earlier, marking early commercial traction.
• The company strengthened its commercial leadership by hiring seasoned executives aimed at accelerating U.S. market penetration.
• International commercialization advanced with the submission and acceptance of a marketing authorization application in Israel and a $1.475 million purchase commitment from Saudi Arabia.
• A 25% workforce reduction and deferred hiring are expected to generate approximately $14.3 million in net cost savings for 2026, partially offset by a one-time severance charge estimated at $0.8 million.
• Ongoing clinical progress includes enrollment in the V012 Phase III dialysis access trial, with interim data expected imminently.